Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Bristol-Myers Squibb (BMY) Shares Decline After Part 2 of Phase 3 CheckMate -227 Did Not Meet Primary Endpoint
July 24, 2019 4:55 PM EDTBristol-Myers Squibb (NYSE: BMY) Shares Decline After Part 2 of Phase 3 CheckMate -227 Did Not Meet Primary Endpoint
Shares declined 4.6%
... More